Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Asset Writedowns and Impairment (2022 - 2025)

Neuraxis' Asset Writedowns and Impairment history spans 4 years, with the latest figure at -$10541.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 434.1% year-over-year to -$10541.0; the TTM value through Sep 2025 reached -$16780.0, down 139.9%, while the annual FY2024 figure was $7395.0, 70.75% down from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was -$10541.0 at Neuraxis, up from -$15761.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $21307.0 in Q2 2022 and bottomed at -$23290.0 in Q4 2022.
  • The 4-year median for Asset Writedowns and Impairment is $3155.0 (2024), against an average of $1832.0.
  • The largest annual shift saw Asset Writedowns and Impairment soared 460.02% in 2024 before it tumbled 434.1% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at -$23290.0 in 2022, then skyrocketed by 181.16% to $18901.0 in 2023, then tumbled by 183.39% to -$15761.0 in 2024, then soared by 33.12% to -$10541.0 in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Asset Writedowns and Impairment are -$10541.0 (Q3 2025), -$15761.0 (Q4 2024), and $3155.0 (Q3 2024).